A study analysed the immune microenvironment of tumors treated with PD-1 inhibitors in a lung adenocarcinoma mouse model and found an upregulation in alternative immune checkpoints of T cells bound to PD-1 antibodies, particularly TIM-3, in mice with tumor progression after PD-1 antibody treatment. Here, HAVCR2 is linked to neoplasm.